Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults (Q24200609)

6

0 references

Anat Gafter-Gvili

4

0 references

Liat Vidal

5

0 references

Noa Eliakim-Raz

1

object named as

Noa Eliakim-Raz

0 references

Eyal Robenshtok

2

object named as

Eyal Robenshtok

0 references

Daphna Shefet

Cochrane Database of Systematic Reviews

3

object named as

Daphna Shefet

0 references

publication date

12 September 2012

0 references

published in

0 references

cites work

Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

21 January 2018

12 December 2020

Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

The FDA and the case of Ketek

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Guidelines for the management of adult lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB4

[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]

21 January 2018

1 reference

12 December 2020

Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]

1 reference

12 December 2020

Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin

1 reference

12 December 2020

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

1 reference

12 December 2020

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

1 reference

12 December 2020

Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

12 December 2020

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

1 reference

12 December 2020

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

12 December 2020

[Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method]

1 reference

12 December 2020

Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia

1 reference

12 December 2020

Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia

1 reference

12 December 2020

Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections

1 reference

12 December 2020

Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group

1 reference

12 December 2020

Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients

1 reference

12 December 2020

Guidelines for the management of adult lower respiratory tract infections - Summary

1 reference

12 December 2020

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin

1 reference

12 December 2020

Ketek--the FDA perspective

1 reference

12 December 2020

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group

1 reference

12 December 2020

A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial

1 reference

12 December 2020

Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults

1 reference

12 December 2020

Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin

1 reference

12 December 2020

Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia

1 reference

12 December 2020

Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin

1 reference

12 December 2020

The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia

1 reference

12 December 2020

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

12 December 2020

The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis

1 reference

12 December 2020

Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.

1 reference

12 December 2020

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

1 reference

12 December 2020

Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization

1 reference

12 December 2020

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

12 December 2020

[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]

1 reference

12 December 2020

A clinical assessment of MedisGroups.

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

1 reference

12 December 2020

[Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia]

1 reference

12 December 2020

Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group

1 reference

12 December 2020

[Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin]

1 reference

12 December 2020

Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections

1 reference

12 December 2020

10.1002/14651858.CD004418.PUB4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

690080

OpenCitations bibliographic resource ID

690080

1 reference